Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT

https://doi.org/10.20996/1819-6446-2017-13-5-684-692

Full Text:

Abstract

Atrial fibrillation (AF) increases the risk of stroke,  therefore long-term anticoagulant therapy is the standard for the treatment of the absolute majority of patients with this arrhythmia. Variants of anticoagulant therapy include vitamin K antagonists, such as warfarin, whose  benefits are long established, but have a number of disadvantages, as well as their alternative – non-vitamin K antagonists – oral anticoagulants, recommended for the treatment of patients with AF with moderate or high risk of stroke. Adherence to pharmacotherapy is important for the long-term effectiveness of any medication; however, in the "real world" in patients with AF relatively low levels of adherence to drugs compared with clinical studies are expected. Experience in several areas of therapy, including the treatment of cardiovascular disease, shows that a low adherence to a constant intake of medications is common. However,  in this respect, simple dosing regimens may be beneficial, since long-term outcomes in AF are likely to depend on adherence to treatment. Rivaroxaban can be given in fixed doses without routine coagulation control, and phase III studies and actual clinical practice have demonstrated its safety and efficacy in patients with AF, including the elderly and patients with concomitant diseases. Taking an oral anticoagulant, not vitamin K antagonists, in particular rivaroxaban, once a day is potentially capable of improving adherence to therapy and the results of stroke prevention in patients with AF.

About the Author

S. G. Kanorskii
Kuban State Medical University
Russian Federation

Sergey G. Kanorskii – MD, PhD, Professor, Head of Chair of Therapy №2.

Sedina ul. 4, Krasnodar, 350063 


References

1. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210

2. Lane D.A., Skjњth F., Lip G.Y.H. et al. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J Am Heart Assoc. 2017;6(5). doi: 10.1161/JAHA.116.005155.

3. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-603. doi: 10.1161/CIR.0000000000000485.

4. Marini C., De Santis F., Sacco S. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115-9. doi: 10.1161/01.STR.0000166053.83476.4a

5. Verma A., Cairns J.A., Mitchell L.B. et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114-30. doi: 10.1016/j.cjca.2014.08.001.

6. January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199- 267. doi: 10.1161/CIR.0000000000000041.

7. Ghannam M., Chugh A. Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation. Heart. 2017;103(14):1129-37. doi: 10.1136/heartjnl-2014-307030.

8. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093- 100. doi: 10.1378/chest.10-0134.

9. Okumura K., Inoue H., Yasaka M. et al. Japanese patients’ and physicians’ preferences for anticoagulant use in atrial fibrillation: results from a discrete-choice experiment. J Health Econ Outcomes Res. 2015;2:207-20.

10. Gladstone D.J., Bui E., Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-40. doi: 10.1161/STROKEAHA.108.516344.

11. Durrant J., Lip G.Y., Lane D.A. Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. Expert Rev Cardiovasc Ther. 2013;11(1):77-90. doi: 10.1586/erc.12.161.

12. Lip G.Y., Tse H.F. Management of atrial fibrillation. Lancet. 2007;370(9587):604-18. doi: 10.1016/S0140-6736(07)61300-2

13. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561.

14. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039.

15. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi: 10.1056/NEJMoa1009638.

16. Amouyel P., Mismetti P., Langkilde L.K. et al. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med. 2009;20(1):63-9. doi: 10.1016/j.ejim.2008.04.005.

17. Holster I.L., Valkhoff V.E., Kuipers E.J., Tjwa E.T. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105-12. doi: 10.1053/j.gastro.2013.02.041

18. Camm A.J., Amarenco P., Haas S. et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145-53. doi: 10.1093/eurheartj/ehv466.

19. Ten Cate H. et al. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11(1):8. doi: 10.1186/1477-9560-11-8.

20. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310. doi: 10.1016/S0149-2918(01)80109-0

21. Boriani G., Laroche C., Diemberger I. et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509-18. doi: 10.1016/j.amjmed.2014.11.026.

22. Perzborn E., Roehrig S., Straub A. et al. https://www.ncbi.nlm.nih.gov/pubmed/?term=Kubitza%20D%5BAuthor%5D&cauthor=true&cauthor_uid=21164526The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61-75. doi: 10.1038/nrd3185.

23. Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16. doi: 10.1007/s40262-013-0100-7.

24. Stampfuss J., Kubitza D., Becka M., Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549-61. doi: 10.5414/CP201812.

25. Weinz C., Schwarz T., Kubitza D. et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1056-64. doi: 10.1124/dmd.108.025569

26. Kubitza D., Becka M., Mueck W. et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12. doi: 10.1111/j.1365-2125.2010.03753.x.

27. Kubitza D., Becka M., Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-21. doi: 10.1016/j.clpt.2005.06.011

28. Graff J., von Hentig N., Misselwitz F. et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47(11):1398-407. doi: 10.1177/0091270007302952

29. Mueck W., Borris L.C., Dahl O.E. et al. Population pharmacokinetics and pharmacodynamics of onceand twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3):453-61. doi: 10.1160/TH07-12-0714

30. Agnelli G., Gallus A., Goldhaber S.Z. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116(2):180-7. doi: 10.1161/CIRCULATIONAHA.106.668020

31. Buller H.R., Lensing A.W., Prins M.H. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112(6):2242-7. doi: 10.1182/blood-2008-05-160143.

32. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-7. doi: 10.1016/j.ahj.2009.11.025.

33. Mueck W., Lensing A.W., Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86. doi: 10.2165/11595320-000000000-00000.

34. Mahaffey K.W., Wojdyla D., Hankey G.J. et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003.

35. Halperin J.L., Hankey G.J., Wojdyla D.M. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008.

36. Bansilal S., Bloomgarden Z., Halperin J.L. et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675-682. doi: 10.1016/j.ahj.2015.07.006.

37. Jones W.S., Hellkamp A.S., Halperin J. et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014;35(4):242-9. doi: 10.1093/eurheartj/eht492.

38. van Diepen S., Hellkamp A.S., Patel M.R. et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6(4):740-7. doi: 10.1161/CIRCHEARTFAILURE.113.000212.

39. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. doi: 10.1093/eurheartj/ehr342.

40. Hankey G.J., Patel M.R., Stevens S.R. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X.

41. Mahaffey K.W., Stevens S.R., White H.D. et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35(4):233-41. doi: 10.1093/eurheartj/eht428.

42. Piccini J.P., Stevens S.R., Lokhnygina Y. et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. doi: 10.1016/j.jacc.2013.02.025.

43. LalibertО F., Cloutier M., Nelson W.W. et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317-25. doi: 10.1185/03007995.2014.907140.

44. Beyer-Westendorf J., Förster K., Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-62. doi: 10.1182/blood-2014-03-563577

45. Beyer-Westendorf J., Förster K., Ebertz F. et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530-8. doi: 10.1093/europace/euu319.

46. Nessel C., Mahaffey K., Piccini J. et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKETAF trial. Chest. 2012;142:84A.

47. Glasziou P., Haynes B. The paths from research to improved health outcomes. Evid Based Med. 2005;10:36-8. doi: 10.1136/ebn.8.2.36

48. Tsai K., Erickson S.C., Yang J. et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013;19(9):e325-32.

49. Bakhai A., Sandberg A., Mittendorf T. et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013;13:108. doi: 10.1186/1471-2261-13-108.

50. Nelson W.W., Song X., Coleman C.I. et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461-9. doi: 10.1185/03007995.2014.933577

51. Kachroo S., Hamilton M., Liu X. et al. https://www.ncbi.nlm.nih.gov/pubmed/?term=Pan%20X%5BAuthor%5D&cauthor=true&cauthor_uid=26799200 Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation. Am J Manag Care. 2016;22(1):e1-8.

52. Davis T.C., Wolf M.S., Bass P.F. 3rd et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med. 2006;145(12):887-94. doi: 10.7326/0003-4819-145-12-200612190-00144

53. Wolf M.S., Curtis L.M., Waite K. et al. Helping patients simplify and safely use complex prescription regimens. Arch Intern Med. 2011;171(4):300-5. doi: 10.1001/archinternmed.2011.39.

54. Clemens A., Haertter S., Friedman J. et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin. 2012;28(2):195-201. doi: 10.1185/03007995.2011.654109

55. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310. doi: 10.1016/S0149-2918(01)80109-0

56. Bae J.P., Dobesh P.P., Klepser D.G. et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18(3):139-46.

57. Coleman C.I., Roberts M.S., Sobieraj D.M. et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669-80. doi: 10.1185/03007995.2012.677419.

58. Laliberté F., Bookhart B.K., Nelson W.W. et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6(3):213-24. doi: 10.1007/s40271-013-0020-5.

59. Benner J.S., Chapman R.H., Petrilla A.A. et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-7. doi: 10.1007/s40520-015-0435-z

60. Giardini A., Martin M.T., Cahir C. et al. Toward appropriate criteria in medication adherence assessment in older persons: Position Paper. Aging Clin Exp Res. 2016;28(3):371-81. doi:

61. Mohammed S., Arabi A., El-Menyar A. et al. Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention. Curr Vasc Pharmacol. 2016;14(4):388-93. doi: 10.2174/1570161113666151030105805

62. Proietti M., Raparelli V., Olshansky B., Lip G.Y. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412-20. doi: 10.1007/s00392-015-0936-y.

63. Palacio A.M., Kirolos I., Tamariz L. Patient values and preferences when choosing anticoagulants. Patient Prefer Adherence. 2015;9:133-8. doi: doi: 10.2147/PPA.S64295.

64. Borg Xuereb C., Shaw R.L., Lane D.A. Patients' and physicians' experiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. Psychol Health. 2016;31(4):436-55. doi: 10.1080/08870446.2015.1116534.

65. Raparelli V., Proietti M., Cangemi R. et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209-18. doi: 10.1160/TH16-10-0757.

66. McHorney C.A., Ashton V., Laliberte F. et al. Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation. American College of Cardiology Conference 2017, Washington, DC, USA, 17-19 March 2017; Poster 1252-306. https://www.ncbi.nlm.nih.gov/pubmed/?term=Lefebvre%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23857628https://www.ncbi.nlm.nih.gov/pubmed/?term=Bailey%20SC%5BAuthor%5D&cauthor=true&cauthor_uid=21357804https://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=17135578


For citation:


Kanorskii S.G. ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT. Rational Pharmacotherapy in Cardiology. 2017;13(5):684-692. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-5-684-692

Views: 433


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)